Thalidomide: 5 agencies, 2004–2020
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused thalidomide: all 7 decisive outcomes across 4 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 15.4 years separate the first record, 1 Nov 2004 at PHARMAC (New Zealand), from the most recent, 15 Apr 2020 at HAS (France).
PHARMAC (New Zealand) changed its position: restricted on 1 Nov 2004, recommended by 10 Mar 2011.
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2020; on this evidence the file is dormant.
Against its own class, thalidomide is an outlier: 100% of its decisive outcomes were positive, where molecules sharing ATC class L04A average 78%.
PHARMAC (New Zealand) was first to assess thalidomide, on 1 Nov 2004; AWMSG (Wales) did not open a file until 17 Mar 2009 — a wide spread of 4.3 years between the earliest and latest system to look at it.
2 of the 5 agencies here assessed thalidomide more than once, PHARMAC (New Zealand) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed thalidomide.
The full ledger for thalidomide reads 6 recommended, 1 superseded and 1 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 15 Apr 2020 | Listing (Transparency Committee) | SMR low · ASMR V | source |
| AWMSG (Wales) | 17 Mar 2009 | In combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged 6… | superseded (full) | source |
| SMC (Scotland) | 12 Jan 2009 | In combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged ≥65 years or ineligible for high dose chemoth… | accepted | source |
| TLV (Sweden) | 19 Dec 2008 | Thalidomide Pharmion beviljas subvention | general subsidy | source |
| PHARMAC (New Zealand) | 1 Nov 2004 | Relapsed or treatment refractory multiple myeloma (brand change) | PTAC advice: Low · decision reached | source |
3 further decisions for thalidomide, across 2 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 8 decisions for thalidomide from 5 agencies, 2004 to 2020. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.